Navigation Links
Elusys Releases New Data On Anthrax Anti-Toxin Administered Via Intramuscular Injection From Three Recent Animal Studies
Date:7/31/2013

challenge with B. anthracis. All control animals developed bacteremia by 56 hours after challenge while 86% (36/42) of animals dosed with ETI-204 never developed detectable levels of bacteremia.

"These data demonstrate the considerable activity obtained with intramuscular (IM) administration of the anti-toxin when given either before or after challenge in animal models of inhalational anthrax. We are extremely pleased that a single dose of ETI-204 demonstrated protection against inhalational anthrax infection," said Leslie Casey, PhD, Vice President, Research. "We look forward, in the very near term, to initiating a clinical study in healthy subjects to assess the pharmacokinetics and tolerability of IM administration in humans."

Anthrax is a life-threatening infectious disease caused by the bacterium Bacillus anthracis and remains one of the nation's top biowarfare threats. Much of the morbidity and mortality of anthrax can be attributed to anthrax toxins. Inhaled anthrax is often fatal, despite treatment with antibiotics. In the 2001 anthrax letter attacks, inhalational anthrax had a fatality rate of approximately 50% in humans infected, even when victims were given antibiotics and supportive hospital care.

ETI-204 is the only anthrax anti-toxin in advanced stages of development that is formulated as a solution and is being investigated for both IV and IM administration. A product that can be given IM as well as IV is highly desirable because it could provide the capability to more rapidly administer product to people outside of a hospital setting or where IV administration is not feasible.

About ETI-204
ETI-204 is a high-affinity, humanized and deimmunized monoclonal antibody that targets the protective antigen of B. anthracis and neutralizes the lethal effects of anthrax toxins by binding to Protective Antigen. It is an investigational agent being deve
'/>"/>

SOURCE Elusys Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Elusys Awarded Additional $50.2 Million Under An Exisiting U.S. Government Contract To Support Final Stages Of Development Of ETI-204, For Treatment Of Inhalational Anthrax
2. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
3. HCCS Releases ICD-10 Countdown Clock With Integrated CMS Twitter Tweets
4. eCareSoft Releases eCS Cirrus™
5. AtheroNova Releases 2011 Financial Results
6. Atlanta LASIK Surgeon Dr. Ashraf Releases YouTube Videos Featuring Patient Testimonials and Discussion of Common Eye Treatments
7. ILVO-T&V Belgium Releases Validation Report of the Charm Sciences Beta-lactam and Tetracycline 2-minute Test for Raw Commingled Milk
8. ISPE Releases New Guidance for Designing and Constructing Packaging, Labeling and Warehousing Facilities
9. Happtique Releases Draft App Certification Program Standards For Public Comment
10. ClearCanvas Releases New Workstation Products Designed to Assist With Image Sharing
11. OneMedPlace Releases Update to Research Report on Amarantus Biosciences Focused on New Positive Ischemic Heart Disease Efficacy Data for MANF in Animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... July 07, 2015 , ... uBiome, the leading microbial genomics ... of microbiome sampling kits and full 16S laboratory analysis. The goal is to fast-track ... will also have access to their own dashboard, enabling them to view and compare ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... ... membership driven community in the biometrical area. What began as a conference for ... global community for various functions in the biometrical area. Statistical Programmers, Data Managers ...
(Date:7/7/2015)... ... July 07, 2015 , ... Currently deployed ... was developed to solve many of the complex logistical and data management ... involve multiple clinical sites and/or remote data coordination centers. , CentrePoint drastically ...
(Date:7/6/2015)... ... July 06, 2015 , ... An optical ... reveal how blood flows in the brain during stroke, providing information that could ... new article published in the journal Neurophotonics describes work at the ...
Breaking Biology Technology:uBiome to Award Grant of up to $100k for Groundbreaking Microbiome Research 2uBiome to Award Grant of up to $100k for Groundbreaking Microbiome Research 3PhUSE Delighted to Welcome Member Number 5.000 2ActiGraph Launches CentrePoint Cloud-based Study Management Software Platform 2ActiGraph Launches CentrePoint Cloud-based Study Management Software Platform 3Reducing Stroke Damage May be Next Application for OCT Technology Now Widely Used in Eye and Vision Healthcare 2Reducing Stroke Damage May be Next Application for OCT Technology Now Widely Used in Eye and Vision Healthcare 3
... PDL BioPharma, Inc. (PDL, the Company) (NASDAQ: ... to market and other conditions, $135 million aggregate principal amount ... Company,s shelf registration statement filed with the U.S. Securities and ... expects to grant the underwriters a 13-day overallotment option to ...
... The U.S. Food and Drug Administration is requesting input ... of a user fee program for biosimilar and interchangeable ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Biological products are produced in ... animal cell, while small molecule drugs are typically made ...
... May 9, 2011 Accuray Incorporated (Nasdaq: ... field of radiosurgery, announced today that the U.S. Securities ... S-4 Registration Statement relating to the previously announced acquisition ... in the registration statement will first be mailed to ...
Cached Biology Technology:PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 2PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 3PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 4PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 5FDA Requests Input on Development of User Fee Program for Biosimilar and Interchangeable Biological Products 2SEC Declares Accuray Form S-4 Registration Statement Effective in Proposed Acquisition of TomoTherapy 2SEC Declares Accuray Form S-4 Registration Statement Effective in Proposed Acquisition of TomoTherapy 3SEC Declares Accuray Form S-4 Registration Statement Effective in Proposed Acquisition of TomoTherapy 4
(Date:6/16/2015)... , June 16, 2015 /CNW Telbec/ - handyem ... centralized around the incorporation of handyem,s HPC-150 portable ... laboratory, the Mo-POD™. This unprecedented model of mobile ... Conference at the Pennsylvania ... June 15 th to 18 th ...
(Date:6/16/2015)... Fingerprint Cards (FPC) raises the revenue guidance for ... at least 340 MSEK to that it will amount to ... growth and orders received the revenue guidance for 2015 is ... will exceed 1,500 MSEK to an updated guidance that revenue ... Due to receipt of orders of touch fingerprint sensors with ...
(Date:6/15/2015)... Conn. , Jun. 15, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces that ... be showcased to media at Digital Experience! @ NYC June ... summer showcase of the latest innovation in technology to over ... will be held at the Metropolitan Pavilion in ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3
... who have high blood sugar before undergoing surgery ... deep vein thrombosis and even pulmonary embolism after ... anesthesiology in the Artificial Pancreas Center at Jefferson ... and his colleagues examined records of nearly 6,500 ...
... light on how tiny molecular motors that transport materials ... , The knowledge could lead to better understanding of ... such as Down syndrome caused by faulty molecular motors, ... researchers said. For example, molecular motors are responsible for ...
... Two Boston University biomedical engineers have won a ... continue groundbreaking research aimed at reducing the cost ... , Boston University Associate Professor of Biomedical Engineering ... chosen for the NIH's National Human Genome Research ...
Cached Biology News:Jefferson scientists find high glucose before surgery raises risk of dangerous complications 2Researchers image molecular motor structural changes 2Researchers image molecular motor structural changes 3Researchers image molecular motor structural changes 4Boston University biomedical engineers win major grant for pursuit of the '$1,000 Genome' 2
... Clone/PAD: ZMD.460. Immunogen: Synthetic peptide ... human C35 protein (chromosome 17 open reading ... Specific for the C35 protein. On ... at ~15 kDa band. Reactivity: Human ...
US Pharmacopoeia Purified-Water/Water-for-Injection Quality Water...
... Primer is designed for sequencing inserts cloned ... V2051, V2061). The primer hybridizes upstream of ... approximately 4050 base pairs upstream of the ... to determine if an insert is cloned ...
Request Info...
Biology Products: